{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epivir&page=2", "query": { "intervention": "Epivir", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epivir&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T19:09:37.073Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04493216", "title": "A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "FTC/TAF", "type": "DRUG" }, { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2020-11-18", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 9, "location_summary": "Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Berkley", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493216" }, { "nct_id": "NCT00043888", "title": "Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "fosamprenavir", "type": "DRUG" }, { "name": "COMBIVIR", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" }, { "name": "TRIZIVIR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 60, "start_date": "2002-01", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Long Beach, California • Newport Beach, California + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043888" }, { "nct_id": "NCT01227824", "title": "A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I" ], "interventions": [ { "name": "GSK1349572 (dolutegravir)", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "GSK1349572 Placebo", "type": "OTHER" }, { "name": "ABC/3TC", "type": "OTHER" }, { "name": "TDF/FTC", "type": "OTHER" }, { "name": "raltegravir Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 828, "start_date": "2010-10-19", "completion_date": "2016-12-27", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227824" }, { "nct_id": "NCT00000903", "title": "Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 444, "start_date": null, "completion_date": "2001-07", "has_results": false, "last_update_posted_date": "2012-05-21", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000903" }, { "nct_id": "NCT03446573", "title": "Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG + 3TC", "type": "DRUG" }, { "name": "TAF based regimen (TBR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 743, "start_date": "2018-01-18", "completion_date": "2022-05-03", "has_results": true, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 54, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 44 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446573" }, { "nct_id": "NCT00124241", "title": "An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "telbivudine", "type": "DRUG" }, { "name": "lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": null, "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2015-05-12", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124241" }, { "nct_id": "NCT00002203", "title": "A Study of Two Anti-HIV Drug Combinations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 6, "location_summary": "Beverly Hills, California • Los Angeles, California • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Annandale", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002203" }, { "nct_id": "NCT01440569", "title": "Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2011-09", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-14", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01440569" }, { "nct_id": "NCT03078556", "title": "Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Dolutegravir + Lamivudine FDC Formulation 1", "type": "DRUG" }, { "name": "Dolutegravir + Lamivudine FDC Formulation 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 154, "start_date": "2017-03-27", "completion_date": "2017-08-18", "has_results": true, "last_update_posted_date": "2019-02-21", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03078556" }, { "nct_id": "NCT06056596", "title": "Lamivudine and Plasma Markers of Inflammation in Retinal Detachment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Retinal Detachment", "Rhegmatogenous Retinal Detachment" ], "interventions": [ { "name": "Lamivudine 300 MG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2024-01-30", "completion_date": "2024-09-06", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-22T19:09:37.073Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056596" } ] }